Associated Papers
All-CLL: A Capture-based Next-generation Sequencing Panel for the Molecular Characterization of Chronic Lymphocytic Leukemia.
López-Oreja I et al.
Hemasphere, 2023
37746159 (PubMed )
Supplement: hs9-7-e962-s002.xlsx › Table_S7
Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY.
Mansouri L et al.
Leukemia, 2023
Characterization of clonal immunoglobulin heavy V-D-J gene rearrangements in Chinese patients with chronic lymphocytic leukemia: Clinical features and molecular profiles.
Deng X et al.
Frontiers in Oncology, 2023
36874132 (PubMed )
Supplement: Table_1.xlsx › Sheet1
Clonally unrelated Richter syndrome are truly de novo diffuse large B-cell lymphomas with a mutational profile reminiscent of clonally related Richter syndrome.
Favini C et al.
British Journal of Haematology, 2022
35829664 (PubMed )
Supplement: BJH-198-1016-s001.xlsx › Table_S4
Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumab.
Bruscaggin A et al.
Blood Advances, 2021
34500472 (PubMed )
Supplement: advancesADV2021004528-suppl2.xlsx › Table_S7
Multiregional sequencing and circulating tumour DNA analysis provide complementary approaches for comprehensive disease profiling of small lymphocytic lymphoma.
Moia R et al.
British Journal of Haematology, 2021
34291829 (PubMed )
Supplement: BJH-195-108-s003.xlsx › Table_S2
Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM).
González-Rincón J et al.
Plos One, 2021
34506616 (PubMed )
Supplement: pone.0257353.s001.xlsx › Table_S3._SNVs
Genetic dynamics in untreated CLL patients with either stable or progressive disease: a longitudinal study.
Ramassone A et al.
Journal of Hematology & Oncology, 2019
31744508 (PubMed )
Supplement: 13045_2019_802_MOESM4_ESM.pdf
Novel Richter Syndrome Xenograft Models to Study Genetic Architecture, Biology, and Therapy Responses.
Vaisitti T et al.
Cancer Research, 2018
Clinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemia.
Nadeu F et al.
Leukemia, 2018
28924241 (PubMed )
Supplement: leu2017291x1.pdf
Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia.
Herling CD et al.
Nature Communications, 2018
29463802 (PubMed )
Supplement: 41467_2018_3170_MOESM4_ESM.xlsx › Somatic_Mutations
The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy.
Landau DA et al.
Nature Communications, 2017
29259203 (PubMed )
Supplement: 41467_2017_2329_MOESM4_ESM.xlsx › Supplementary_Data_2
EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia.
Young E et al.
Leukemia, 2017
Genomic characterization of high-count MBL cases indicates that early detection of driver mutations and subclonal expansion are predictors of adverse clinical outcome.
Barrio S et al.
Leukemia, 2017
27469216 (PubMed )
Supplement: NIHMS793139-supplement-3.xlsx › S3
Mutations driving CLL and their evolution in progression and relapse.
Landau DA et al.
Nature, 2015
26466571 (PubMed )
Supplement: NIHMS715090-supplement-Supplementary_Table_10.xlsx › CCF_DP_clustering
Monoclonal B-cell lymphocytosis is characterized by mutations in CLL putative driver genes and clonal heterogeneity many years before disease progression.
Ojha J et al.
Leukemia, 2014
Acquired initiating mutations in early hematopoietic cells of CLL patients.
Damm F et al.
Cancer Discovery, 2014
Select a paper to view details